- Cybin has completed more than 20 pre-clinical studies in record time.
- Company is advancing two new therapeutic candidates with enhanced, improved properties.
- Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs.
Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, has completed key research studies both in vitro and in vivo. The company recently announced that it had completed its 20th pre-clinical study and had progressed two psychedelic investigational new drug candidates: CYB003 and CYB004 (https://ibn.fm/jDvFz).
The studies were completed in record time, the company reported, in part because of close collaboration with its partners and contractors. “Excellent teamwork and fully supportive partners have greatly facilitated the advancement of these two new therapeutic candidates with enhanced and improved properties,” said Cybin chief R&D officer Michael Palfreyman. “We look forward to rapid progress towards clinical studies.”
The completed studies were focused on evaluating proprietary Cybin technologies, and more than 20 definitive research studies designed by the Cybin scientists were conducted. Results of the studies have led to the progression CYB003 and CYB004, two proprietary psychedelic therapeutics which have entered into full IND-enabling studies.
These studies are in preparation for upcoming clinical testing designed to analyze the effectiveness of these therapeutics in the treatment of serious psychiatric conditions with high unmet medical needs. The company has also initiated an API manufacturing contract with a strategic pharmaceutical manufacturing partner. According to Cybin, the pre-clinical studies of CYB003 and CYB004 candidates included API synthesis and optimization to prove that the two psychedelic molecules show significant in vivo modifications of pharmacokinetics consistent with proof of concept.
These two studies are only a part of Cybin’s impressive pipeline. Currently the company is developing more than 50 proprietary psychedelic molecules and multiple proprietary delivery mechanisms and supportive technology platforms. The company plans to continue to progress its novel next-generation psychedelics based on well-known scaffolds including psilocybin, DMT, MDMA with improved bioavailability and optimized pharmacokinetic profiles to provide shorter duration of action with the potential for reduced side effects.
“Our internal research and development team, along with an extensive network of partners, has progressed CYB003 and CYB004 into IND-enabling studies at an impressive pace,” said Cybin CEO Doug Drysdale. “I am in no doubt we have the best team in this sector and the right team to progress these exciting future treatments into clinical studies over the next 12 months.”
Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug- discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com